A mesenchymal stem cell endothelial differentiation inducer
By using mesenchymal stem cell endothelial differentiation inducers composed of factors such as vascular endothelial growth factor and combined with specific culture media, the problems of long and low efficiency of mesenchymal stem cell endothelial cell differentiation induction time in the prior art are solved, and high efficiency is achieved. Induction of endothelial cells with strong activity has promoted the clinical application of cell therapy.
Patent Information
- Application Number
- CN202211648480.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-12-21
AI Technical Summary
The prior art methods for inducing endothelial cell differentiation in mesenchymal stem cells have too long induction time, low efficiency and poor activity of endothelial cells, which limits the clinical application of cell therapy.
The mesenchymal stem cell endothelial differentiation inducer consisting of factors such as vascular endothelial growth factor, bone formation protein-4, tumor necrosis factor α, erythropoietin, icariin, rapamycin, testosterone and metformin, combined with Specific culture medium to achieve efficient inducing differentiation.
It significantly improves the endothelial differentiation efficiency of mesenchymal stem cells, has strong cell activity after induction, and has no ethical problems and is highly safe.
Smart Images

Figure CN115820540B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of stem cell induced differentiation, and specifically relates to a mesenchymal stem cell directional differentiation inducer. Background Art
[0002] Endothelial cells belong to the epithelial cell type and constitute the innermost layer of the entire circulatory vascular system. In addition to being a barrier between peripheral blood and the vascular wall, endothelial cells also have important physiological functions such as secretion, metabolism, synthesis, and immune regulation. At present, foreign scholars have used endothelial cells to treat ischemic diseases and have achieved certain results. However, due to the difficulty in obtaining endothelial cells and the fact that they are terminally differentiated cells and cannot be expanded in large quantities, they cannot meet the large number of cells required for transplantation or construction of tissue engineering blood vessels. Therefore, the selection of a seed cell that is easy to obtain clinically and easy to expand in vitro has become a hot topic in vascular tissue engineering research.
[0003] Mesenchymal stem cells are a type of stem cell with multidirectional differentiation potential. They originate from the mesoderm during embryonic development and have the potential to differentiate into a variety of mesodermal cell lines, including osteoblasts, adipocytes, chondrocytes, nerve cells, liver cells, pancreatic islet cells, epidermal cells, endothelial cells, etc. Mesenchymal stem cells are widely available and have no ethical restrictions. They are easy to separate and proliferate in vitro. They still maintain multidirectional differentiation potential after multiple divisions and passages. Clinical trials so far have not found serious side effects of mesenchymal stem cells, making them an ideal seed cell for cell therapy and regenerative medicine.
[0004] There are not many reports in the literature on the use of mesenchymal stem cells to induce endothelial stem cell differentiation in vitro. The induction methods are relatively similar, and the differentiation rate is also low. These methods include adding factors such as vascular endothelial growth factor and bone morphogenetic protein-4 to the culture medium, as well as hypoxic environments and gelatin-coated culture plates to induce differentiation. There is no large-scale and efficient method for inducing endothelial cells in vitro, which limits the development of clinical applications of cell therapy. A new method for inducing differentiation is urgently needed. Summary of the invention
[0005] In order to solve the problems existing in the prior art, the purpose of the present invention is to provide an inducer of endothelial differentiation of mesenchymal stem cells, which can induce the differentiation of mesenchymal stem cells into endothelial cells. At present, most inducers of endothelial differentiation of mesenchymal stem cells have the problems of too long induction time, low induction efficiency, and poor activity of endothelial cells obtained after induction.
[0006] To achieve the above purpose, the technical solution adopted by the present invention is: a mesenchymal stem cell endothelial differentiation inducer, which is composed of vascular endothelial growth factor, bone morphogenetic protein-4, tumor necrosis factor α, erythropoietin, icariin, rapamycin, testosterone, metformin, and trametinib. After adding complete culture medium, the effective concentrations of each component are vascular endothelial growth factor 20-40μg / L, bone morphogenetic protein-4 20-40μg / L, tumor necrosis factor α 5-10μg / L, erythropoietin 5-10μg / L, icariin 5-10mg / L, rapamycin 5-10μg / L, testosterone 20-40μg / L, metformin 20-40μg / L, and trametinib 20-40μg / L. The complete culture medium is Keratinocyte-SFM, a serum-free culture medium for human mesenchymal stem cells, or DMEM / F12+10% FBS.
[0007] Preferably, a mesenchymal stem cell endothelial differentiation inducer, after adding complete culture medium, the concentrations of each component are vascular endothelial growth factor 30μg / L, bone morphogenetic protein-4 30μg / L, tumor necrosis factor α 8μg / L, erythropoietin 8μg / L, icariin 8mg / L, rapamycin 7μg / L, testosterone 30μg / L, metformin 30μg / L, trametinib 30μg / L. The complete culture medium is Keratinocyte-SFM, serum-free culture medium for human mesenchymal stem cells or DMEM / F12+10%FBS.
[0008] The mesenchymal stem cell endothelial differentiation inducer of the present invention adopts cytokines combined with small molecule compounds to efficiently induce mesenchymal stem cells to differentiate into endothelial cells, greatly improves the induction differentiation efficiency, has strong cell activity after induction, has no ethical issues, and is highly safe. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 CD31-positive endothelial cells after mesenchymal stem cell induction (×200);
[0010] Figure 2 CD144-positive endothelial cells after mesenchymal stem cell induction (×200);
[0011] Figure 3 KDR (vascular endothelial growth factor receptor)-positive endothelial cells after mesenchymal stem cell induction (×200);
[0012] Figure 4 Comparison of the induction efficiency of the induction agent of the present invention and the traditional method for inducing human adipose mesenchymal stem cells;
[0013] Figure 5Comparison of the induction efficiency of human umbilical cord mesenchymal stem cells induced by the inducing agent of the present invention and the traditional method. DETAILED DESCRIPTION
[0014] The experimental methods in the following examples are conventional methods unless otherwise specified. The instruments, apparatuses and reagents used in the experiments can all be obtained through commercial channels.
[0015] Example 1 Mesenchymal stem cell endothelial differentiation inducer, the following raw materials were dissolved according to their respective characteristics, and human mesenchymal stem cell serum-free culture medium (LONZA, product number 00190632) was used as the matrix, and the content of each component was fixed to 1000 ml as follows: vascular endothelial growth factor (VEGF, brand PeproTech, product number 96-100-20-2) 20 μg, bone morphogenetic protein-4 (BMP-4, brand Sigma, product number SRP3016-10 μg) 20 μg, tumor necrosis factor α (TNF-α, brand PeproTech, product number 96-100-00AB-10 μg) 5 μg, erythropoietin (EPO, brand PeproTech, product number CYT-201) 5 μg, icariin (Shanghai Microcrystal Biotechnology, 489-32-7,20mg) 5μg, rapamycin (brand TargetMol, product number T1537) 5μg, testosterone (brand Sigma, product number T1500) 20μg, metformin (brand Sigma, product number D150959-5G) 20μg, trametinib (brand Meilun Bio, product number MB5401) 20μg, mix well and filter to sterilize.
[0016] Example 2 Mesenchymal stem cell endothelial differentiation inducer, the following raw materials are dissolved according to their respective characteristics, DMEM / F12+10% FBS is used as the matrix, and the volume of each component is adjusted to 1000 ml as follows: VEGF 40μg, BMP-4 40μg, TNF-α 10μg, EPO 10μg, icariin 10μg, rapamycin 10μg, testosterone 40μg, metformin 40μg, trametinib 40μg, mix well and filter to sterilize.
[0017] Example 3 Mesenchymal stem cell endothelial differentiation inducer, the following raw materials are dissolved according to their respective characteristics, Keratinocyte-SFM (brand Gibco, product number: 17005042) is used as the matrix, and the content of each component is adjusted to 1000 ml as follows: VEGF 30μg, BMP-4 30μg, TNF-α 8μg, EPO 8μg, icariin 8μg, rapamycin 7μg, testosterone 30μg, metformin 30μg, trametinib 30μg, mix well and filter to sterilize.
[0018] Example 4 Mesenchymal stem cell endothelial differentiation inducer, the following raw materials are dissolved according to their respective characteristics, and human mesenchymal stem cell serum-free culture medium (LONZA, product number 00190632) is used as the matrix, and the content of each component is adjusted to 1000 ml as follows: VEGF 30μg, BMP-4 30μg, TNF-α 8μg, EPO 8μg, icariin 8μg, rapamycin 7μg, testosterone 30μg, metformin 30μg, trametinib 30μg, mix well and filter to sterilize.
[0019] Example 5 Using the inducer prepared in Example 4, an experiment was conducted on the induction of endothelial cell differentiation of human adipose-derived mesenchymal stem cells (AD-MSCs)
[0020] 1. Primary culture of adipose-derived mesenchymal stem cells in vitro: The post-liposuction fluid was centrifuged at 800 r / min for 3 min, and the floating adipose tissue on the upper layer was retained. The cells were rinsed with phosphate buffered saline (PBS), and centrifuged twice at 800 r / min for 5 min, retaining the upper layer of fat. An equal volume of 0.2% collagenase was added, and the cells were digested on a shaking table at 37°C for 30 min. The paste-like digestion solution was filtered with a 100-mesh stainless steel filter, centrifuged at 1500 r / min for 5 min, and the precipitate was resuspended in 1 ml of DME / F12, rinsed with PBS, centrifuged at 1000 r / min for 8 min, resuspended in cell culture medium, and 5×10 5 / ml inoculation; incubate in a 37℃, 5% CO2 incubator, and change the medium after 3 days. When the cells grow to 80% confluence, digest with 0.25% trypsin and subculture.
[0021] 2. Identification of Adipose-Derived Mesenchymal Stem Cells
[0022] (1) P4 AD-MSCs were taken and cell surface markers were detected by flow cytometry. The results are shown in Table 1.
[0023] Table 1 Detection of surface markers of AD-MSCs
[0024]
[0025] Among them, the expression of positive markers CD29, CD73, CD90, and CD49d was greater than 95%, and the expression of negative markers CD31, CD34, CD45, and HLA-DR was less than 2%, proving that the cells were adipose mesenchymal stem cells (MSCs).
[0026] 3. Induced differentiation of adipose-derived mesenchymal stem cells into endothelial cells: P4 AD-MSCs were taken and 5*10 5 The cells were inoculated into 6-well plates and replaced with the induction medium of the present invention after overnight attachment for 8 consecutive days. A blank control group and a positive control group were also set up. The groups are shown in Table 2.
[0027] Table 2 Induced differentiation groups
[0028]
[0029] 4. Immunohistochemical detection of CD31, CD144, and KDR expression: Five fields of view under a light microscope (×200) were randomly selected from each group of cell slides to count the number of cells positively stained with CD31, CD144, and KDR. The experiment was repeated three times.
[0030] Results: Cell immunohistochemical staining revealed that there were no cells with positive staining of CD31, CD144, and KDR in the blank control group. The number of cells with positive staining of CD31, CD144, and KDR in the inducer of the present invention was significantly greater than that in the experimental group 2 (positive control), indicating that the inducer of the present invention is significantly superior to the traditional inducer. Figure 4 The results were statistically significant. Figure 1 , 2 , 3 show cells positively stained with CD31, CD144, and KDR, respectively.
[0031] Example 6 Using the inducing agent prepared in Example 4, an endothelial cell differentiation experiment was performed on human umbilical cord mesenchymal stem cells (UC-MSCs)
[0032] 1. Isolation and culture of umbilical cord mesenchymal stem cells (tissue explant culture method)
[0033] (1) Add 30 ml of saline solution to the umbilical cord collection bottle to initially wash the umbilical cord.
[0034] (2) Use sterile forceps to transfer the umbilical cord to a 10 cm sterile culture dish. Use sterile surgical scissors to cut the umbilical cord into several sections of approximately 2 cm. Add physiological saline to wash the blood clot until the blood stains are basically removed and the washing solution is clear.
[0035] (3) Removing blood vessels: Two arteries and one vein are removed according to the spiral path of the blood vessels.
[0036] (4) Separation of Wharton's jelly: The white connective tissue between the amnion and the blood vessels is Wharton's jelly. Tear it off with long-handled toothed forceps and place it in a sterile dish.
[0037] (5) Washing red blood cells: Add 10 ml of water for injection into a sterile dish and wash the colloid for 1 min. Wash twice in total.
[0038] (6) Colloid weighing: Transfer the washed Wharton's jelly into a 50 ml centrifuge tube and record the weight.
[0039] (7) Tissue homogenization: Use sterile long-handled surgical scissors to cut the tissue into 1 mm pieces in a centrifuge tube. 3The shearing time is 15 to 20 minutes for the tissue homogenate block of about 100 μm.
[0040] (8) Fixed volume seed bottle: according to the weight of the colloid, add an appropriate amount of umbilical cord MSC special culture medium, and the fixed volume tissue homogenate concentration is 0.4g / ml. After the homogenate is evenly mixed with an electric pipette, add 10 ml of umbilical cord MSC special culture medium every 75cm 2 Inoculate 1 ml of tissue homogenate (i.e. 0.4 g / 75 cm 2 ), add 15 ml of umbilical cord MSC serum-free culture medium (LONZA, 00190632) into a T75 culture flask, shake the culture flask to mix well, and then culture.
[0041] (9) Culture conditions: CO2 constant temperature and humidity incubator, parameters: (37±0.5)℃, CO2 volume fraction: (5±0.2)%.
[0042] (10) Primary culture: Change half of the medium every 4 to 5 days for primary culture (it is planned to use a plate centrifuge. After initial centrifugation in the culture bottle, remove half of the medium, add half of the fresh medium, and resuspend the tissue block for culture). After 14 to 16 days of primary culture, the P0 cell density reaches 80% to 90%, and digestion and subculture are performed.
[0043] (11) P0 cell passage: digestion enzyme is 0.125% Trypsin-0.01% EDTA solution, per 75 cm 2 Add 1-1.5 ml of digestive enzyme solution, digestion time is 40-60 seconds, add 2-3 ml of serum-free culture medium and blow repeatedly on the bottom of the bottle, transfer to a 50 ml centrifuge tube, add 5 ml of physiological saline to the original culture bottle to rinse the bottle wall, add to the centrifuge tube to make up to 50 ml, and count the total number of cells.
[0044] (12) Washing, inoculation and subculturing: Centrifugation parameters: 250 g / min, 10 min. After removing the supernatant, add fresh culture medium to make up the volume and inoculate into a new culture bottle. The cell density for subculturing is (6-8)×10 5 / 75cm 2 .
[0045] (13) Cell culture and subculture: After P1, the medium was changed twice a week and subcultured every 3-4 days. The cell fusion should be 80%-90% during subculture, and the cell density should be (6-8)×10 5 / 75cm 2 .
[0046] 2. Identification of umbilical cord mesenchymal stem cells
[0047] (1) P4 umbilical cord mesenchymal stem cells were obtained and cell surface markers were detected by flow cytometry. The flow cytometry results are shown in Table 3.
[0048] Table 3 Detection of surface markers of UC-MSCs
[0049]
[0050] Among them, the expression of positive markers CD29, CD73, CD90, and CD105 was greater than 95%, and the expression of negative markers CD14, CD34, CD45, and HLA-DR was less than 2%, proving that the cells were MSCs.
[0051] 3. Umbilical cord mesenchymal stem cells were induced to differentiate into endothelial cells: P4 UC-MSCs were taken and 5*10 5 The cells were inoculated in 6-well plates and replaced with the induction medium of the present invention after overnight attachment for 8 consecutive days. A blank control group and a positive control group were set up at the same time. The groups are shown in Table 4.
[0052] Table 4 Induced differentiation groups
[0053]
[0054] 4. Immunohistochemical staining was used to detect the expression of CD31, CD144 and KDR in each group: 5 fields of view under a light microscope (×200) were randomly selected from each group of cell slides to count the number of cells positive for CD31, CD144 and KDR immunohistochemical staining, and the experiment was repeated 3 times.
[0055] Results: Cell immunohistochemical staining showed that there were no cells with positive staining of CD31, CD144 and KDR in the blank control group, while the number of cells with positive staining of CD31, CD144 and KDR in the inducer of the present invention was significantly more than that in the experimental group 2 (positive control), indicating that the inducer of the present invention is significantly superior to the traditional inducer. Figure 5 The results were statistically significant.
Claims
1. A mesenchymal stem cell endothelial differentiation inducer, Features: The invention is composed of vascular endothelial growth factor, bone morphogenetic protein-4, tumor necrosis factor α, erythropoietin, icariin, rapamycin, testosterone, metformin and trametinib; after adding complete culture medium, the concentrations of the components are as follows: vascular endothelial growth factor 20-40 μg / L, bone morphogenetic protein-4 20-40 μg / L, tumor necrosis factor α 5-10 μg / L, erythropoietin 5-10 μg / L, icariin 5-10 mg / L, rapamycin 5-10 μg / L, testosterone 20-40 μg / L, metformin 20-40 μg / L and trametinib 20-40 μg / L; the complete culture medium is Keratinocyte-SFM, serum-free culture medium for human mesenchymal stem cells or DMEM / F12+10% FBS.
